Healthy Inc > Blog > Co-trimoxazole BP/USP/IP
Posted on:

What is Sulphamethoxazole and Trimethoprim tablets used for?

In the pharmaceutical industry, the combination of Sulfamethoxazole and Trimethoprim (SMZ-TMP)—also known as Co-trimoxazole—is a classic example of synergistic antimicrobial therapy. As a pharmacist, I view this as a powerful “sequential blockade” tool, where the two components work together to inhibit bacterial folic acid synthesis far more effectively than either could alone.

Primary Clinical Uses

  • Urinary Tract Infections (UTIs): Often a first-line treatment for uncomplicated UTIs, pyelonephritis, and prostatitis caused by susceptible strains of E. coli or Klebsiella.

  • Respiratory Infections: Used for acute exacerbations of chronic bronchitis and certain types of pneumonia.

  • Pneumocystis Jirovecii Pneumonia (PJP): The “gold standard” for both the treatment and prophylaxis of PJP in immunocompromised patients (such as those with HIV/AIDS).

  • Gastrointestinal Infections: Effective against Shigellosis, Traveler’s Diarrhea, and Cholera.

  • MRSA Skin Infections: Increasingly utilized for community-acquired Methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections.

Mechanism of Action: The Sequential Blockade

SMZ-TMP is bactericidal because it inhibits two consecutive steps in the biosynthesis of nucleic acids and proteins essential to many bacteria:

Sulfamethoxazole: A sulfonamide that competitively inhibits the enzyme dihydropteroate synthase. It mimics PABA (para-aminobenzoic acid), preventing the bacteria from synthesizing dihydrofolic acid.

Trimethoprim: It binds to and reversibly inhibits the next enzyme in the chain, dihydrofolate reductase, preventing the reduction of dihydrofolic acid to tetrahydrofolic acid (the active form of folate).

By attacking two points in the same metabolic pathway, the combination significantly reduces the development of bacterial resistance and enhances the overall potency.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, SMZ-TMP (Standard 400 mg/80 mg or DS 800 mg/160 mg) is a high-volume essential:

  • Fixed-Dose Ratio (5:1): As a WHO-GMP manufacturer, we strictly maintain the 5:1 ratio of Sulfamethoxazole to Trimethoprim. This ratio is optimized to achieve a steady-state plasma concentration ratio of 20:1, which is the peak synergistic level in the blood.

  • Solubility & Dissolution: Sulfamethoxazole is poorly soluble in water. We utilize specific granulation and disintegration agents to ensure the tablet meets pharmacopeial dissolution standards (BP/USP/IP), ensuring maximum bioavailability.

  • Global Tender Staple: Because it is on the WHO Model List of Essential Medicines, it is a constant requirement for government health tenders and B2B distributors in Africa and Southeast Asia.

  • Packaging for Stability: We prioritize PVC/PVDC or Alu-Alu blister packaging to protect the formulation from moisture, ensuring a 36-month shelf life for export to Zone IVb climates.

Co -Trimoxazole Tablets Tablet

 

Posted on:

What is Co-Trimoxazole Sulfamethoxazole Trimethoprim used for?

In the pharmaceutical industry, the combination of Sulfamethoxazole and Trimethoprim (SMZ-TMP)—clinically referred to as Co-trimoxazole—is a classic example of synergistic antimicrobial therapy. As a pharmacist, I characterize this as a “sequential blockade” antibiotic, which remains a staple in both community and hospital settings due to its broad-spectrum efficacy and excellent tissue penetration.

Primary Clinical Uses

  • Urinary Tract Infections (UTIs): A primary treatment for acute uncomplicated cystitis and pyelonephritis, particularly those caused by E. coli or Klebsiella species.

  • Pneumocystis Jirovecii Pneumonia (PJP): The “gold standard” for both the treatment and prophylaxis of PJP in immunocompromised patients (e.g., those with HIV/AIDS).

  • Respiratory Tract Infections: Used for acute exacerbations of chronic bronchitis and acute otitis media in children.

  • Gastrointestinal Infections: Indicated for Shigellosis and Traveler’s Diarrhea.

  • MRSA Management: Increasingly utilized as a cost-effective oral option for treating community-acquired Methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections.

Mechanism of Action: The Sequential Blockade

The synergy of this combination is achieved by inhibiting two consecutive steps in the bacterial synthesis of Tetrahydrofolic acid (essential for DNA production):

Sulfamethoxazole: Acts as a structural analog of PABA, competitively inhibiting the enzyme dihydropteroate synthase.

Trimethoprim: Reversibly inhibits the enzyme dihydrofolate reductase.

By targeting the same metabolic pathway at two different points, the combination becomes bactericidal, whereas each component used alone is typically only bacteriostatic.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, SMZ-TMP is a high-volume, essential medicine requiring specific technical rigor:

  • Fixed-Dose Ratio (1:5): Whether in standard (80mg/400mg) or Double Strength (160mg/800mg) formats, maintaining the 1:5 ratio is critical to achieving the 1:20 plasma concentration ratio required for peak synergy.

  • API Handling: As a WHO-GMP manufacturer, we manage the slightly acidic nature of Sulfamethoxazole and the basic nature of Trimethoprim during the granulation process to ensure final tablet stability and uniform dissolution.

  • Stability for Export: This is a core product for international B2B distributors and government health tenders. We utilize Alu-Alu or high-grade PVC/PVDC blister packaging to ensure a 36-month shelf life in Zone IVb (hot and humid) climates like Africa and Southeast Asia.

  • Regulatory Compliance: Our Mumbai-based facility provides complete CTD/eCTD Dossiers and stability data (BP/USP/IP) to support our partners in global registration.

Co -Trimoxazole Tablets Tablet

 

Add to cart